Baier P K, Eggstein S, Wolff-Vorbeck G, Baumgartner U, Hopt U T
University of Freiburg, Department of Surgery, Freiburg, Germany.
Anticancer Res. 2005 Sep-Oct;25(5):3581-4.
Chemokines (CKs) may promote antitumor immunity in cancer, act as tumor growth factors, influence metastatic spreading or angiogenesis. The purpose of this study was to investigate whether CK expression is altered in colorectal carcinomas compared to normal mucosa and to elucidate its possible clinico-pathological implications.
The levels of CCL2 (MCP-1), CCL4 (MIP-1beta), CCL5 (RANTES), CXCL 1 (GRO-alpha), CXCL 5 (ENA-78) and CXCL 8 (IL-8) were investigated in 10 colorectal carcinomas and their corresponding normal mucosa by the use of ELISA.
All CK analyzed, with the exception of CCL5 (RANTES), were expressed at a significantly higher level in malignant tissue.
Therapeutic studies in colon carcinomas should, therefore, focus more on the neutralization of CKs than on their application.
趋化因子（CKs）可能在癌症中促进抗肿瘤免疫、充当肿瘤生长因子、影响转移扩散或血管生成。本研究的目的是调查与正常黏膜相比，结直肠癌中CK表达是否改变，并阐明其可能的临床病理意义。
通过酶联免疫吸附测定法（ELISA）对10例结直肠癌及其相应的正常黏膜中CCL2（单核细胞趋化蛋白-1，MCP-1）、CCL4（巨噬细胞炎性蛋白-1β，MIP-1β）、CCL5（调节激活正常T细胞表达和分泌因子，RANTES）、CXCL 1（生长调节致癌基因α，GRO-α）、CXCL 5（上皮中性粒细胞激活肽78，ENA-78）和CXCL 8（白细胞介素-8，IL-8）的水平进行了研究。
除CCL5（RANTES）外，所有分析的CK在恶性组织中的表达水平均显著更高。
因此，结肠癌的治疗研究应更多地关注趋化因子的中和作用而非其应用。
